Veracyte, Inc.
http://www.veracyte.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Veracyte, Inc.
JPM 2024: ‘Economic Engine:’ Genomics News Abound From Exact, Guardant And Veracyte
The three genomics players all announced preliminary results prior to speaking, and all had more news to add about their recent success and their plans to grow the demand for cancer diagnostics.
Mysterious Perlmutter-Helmed Start-Up Eikon Raises $517.8m
Eikon launched in 2021 with $148m in series A venture capital and former Merck R&D head Roger Perlmutter as its CEO, but even with half a billion dollars in fresh cash, the firm has not revealed its therapeutic focus.
Veracyte Continues Cancer IVD Expansion By Acquiring HalioDx For $318M
The deal is Veracyte’s second major acquisition in cancer diagnostics in 2021 after agreeing to acquire Decipher Biosciences in March.
Dealmaking Quarterly Statistics, Q1 2021: Boston Scientific, Roche Start The Year With Billion-Dollar-Plus Acquisitions
During the first quarter, medical device company mergers and acquisition totalled $10.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $5bn.
Company Information
- Industry
-
In Vitro Diagnostics
- Cytology
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
-
- Allegro Diagnostics Corporation
- GenomeDx Inc.
- Decipher BioSciences Inc.
- HalioDx Inc.
- Inserm Transfert
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice